Compare GTEC & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GTEC | NXL |
|---|---|---|
| Founded | 2006 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.0M | 20.1M |
| IPO Year | N/A | 2022 |
| Metric | GTEC | NXL |
|---|---|---|
| Price | $1.01 | $0.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 223.8K | ★ 245.9K |
| Earning Date | 11-07-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.92 | N/A |
| Revenue | ★ $86,168,664.00 | $156,931.00 |
| Revenue This Year | $5.64 | $38.28 |
| Revenue Next Year | $3.93 | $185.71 |
| P/E Ratio | $1.04 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.92 | $0.70 |
| 52 Week High | $2.92 | $4.49 |
| Indicator | GTEC | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 42.32 | 38.52 |
| Support Level | $0.92 | $0.93 |
| Resistance Level | $1.09 | $1.12 |
| Average True Range (ATR) | 0.09 | 0.10 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 25.71 | 15.77 |
Greenland Technologies Holding Corp is a developer of quality solutions in the material handling industry. It is a transmission and drivetrain systems provider for material handling equipment such as forklift trucks for industrial and logistic applications. Geographically, the company has its presence in Domestic and International markets and earns majority of the revenue from Domestic Sales.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.